Singapore markets open in 7 hours 14 minutes

Galera Therapeutics, Inc. (GRTX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.1920+0.0022 (+1.16%)
As of 01:45PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.1898
Open0.1852
Bid0.1911 x 100
Ask0.1965 x 200
Day's range0.1852 - 0.2040
52-week range0.0850 - 3.5900
Volume1,450,986
Avg. volume2,067,144
Market cap10.443M
Beta (5Y monthly)2.17
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • GlobeNewswire

    Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates

    Company continues to evaluate strategic options to maximize shareholder valueMALVERN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided recent corporate updates. "As a result of last year’s FDA request for a

  • GlobeNewswire

    Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

    FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended Se

  • GlobeNewswire

    Galera Announces Receipt of Type A Meeting Minutes and Strategic Update

    FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential strategic alternatives to maximize shareholder value MALVERN, Pa., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy